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The Bush Administration's Global AIDS Promises-and
Praxis
Asia Russell*
In other words, we want to join you in the war against the pandemic of AIDS. We
want to be on your side in a big way .... I believe we have a responsibility-my
country has got a responsibility. We are a great nation, we're a wealthy nation. We
have a responsibility to help a neighbor in need, a brother and sister in crisis. And
that's what I'm here to talk about.
-President George Bush, 2003'
INTRODUCTION
In Senegal on July 7, 2003, President Bush began his five-country, five-
day tour of sub-Saharan Africa, the region most devastated by the AIDS
pandemic. Mr. Bush's public statements during his brief time in Africa
characterized the United States as a global leader, willing and able to
confront global AIDS.3 The President's Emergency Plan for AIDS Relief
(PEPFAR), a bilateral program announced during Mr. Bush's 2003 State of
the Union address, was held up as evidence of the United States'
commitment. PEPFAR will commit approximately $10 billion in new
money and $15 billion total over five years to global AIDS treatment and
prevention in twelve African and two Caribbean countries. 4 PEPFAR's
* Director of International Health Policy, Health Global Access Project (HealthGAP).
1. Pres. George W. Bush, Remarks to the AIDS Support Organization (TASO) Centre
at Entebbe, Uganda Uuly 11, 2003), http://www.state.gov/p/af/rls/rm/22366.htm (last
visited Dec. 16, 2003).
2. UNAIDS, REPORT ON THE GLOBAL HIV/AIDS EPIDEMIC 22 (July 2002).
3. See, e.g., Bush, supra note 1;Jim Fisher-Thompson, Bush Welcomed Exuberantly in
Botswana, WASH. FILE (International Information Programs, U.S. State Dep't),July 10, 2003,
available at http://usinfo.state.gov/regional/af/potus2003/a3071002.htm (last visited Dec.
16, 2003).
4. Pres. George W. Bush, State of the Union at the U.S. Capitol (Jan. 28, 2003),
available at http://www.whitehouse.gov/news/releases/2003/01/20030128-19.html (last
visited Dec. 27, 2003).
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clinical goals are to avert seven million new HIV infections, start two
million people on antiretroviral treatment, and extend care to ten million
HIV affected people. The initiative also described a plan to set United
States contributions to the Global Fund To Fight AIDS, Tuberculosis, and
Malaria (Global Fund) at $200 million per year starting in 2004.2 These are
welcome steps, but they are countered by other United States actions that
undermine vital multilateral AIDS interventions, likely with a negative
impact on the viability and success of the President's own program.
For example, during President Bush's visit to Botswana, he remarked
that "the average citizen cares deeply about the fact that people are dying
in record numbers because of HIV/AIDS. We cry for the orphan. We care
for the mom who is alone. We are concerned about their plight, and
therefore, will respond as generously as we can."6 However, less than one
week after President Bush's return from his five-country tour of Africa,
White House officials began obstructing the efforts of Congressional
appropriators to increase United States funding of the Global Fund for
fiscal year 2004 to a maximum of $1 billion, an amount beyond the $200
million requested by President Bush.' The recently appointed clinical
director of PEPFAR and the current director of the Office of National
AIDS Policy, Dr. Joe O'Neill, made a series of arguments in letters to
Congressional leadership, claiming that insufficient infrastructure exists to
absorb the additional $1 billion authorized by Congress, despite extensive
evidence to the contrary.8
5. Press Release, The White House, Fact Sheet: The President's Emergency Plan for
AIDS Relief (Jan. 29, 2003), available at
http://www.whitehouse.gov/news/releases/2003/01/20030129-1.html (last visited Dec. 29,
2003).
6. Pres. George W. Bush, Remarks by President Bush and President Mogae of
Botswana in a Photo Opportunity (July 10, 2003), available at
http://usinfo.state.gov/regional/af/potus2003/a3071OO2.htm (last visited Dec. 13, 2003).
7. See, e.g., Letter from Dr. Joseph O'Neill, Director, Office of National AIDS Policy, to
Rep. Jim Kolbe, US House of Representatives (July 16, 2003), available at
http://www.globalaidsalliance.org/oneillmemo.html (last visited Dec. 29, 2003); Letter
from Dr. Joseph O'Neill, Director, Office of National AIDS Policy, to Bill Frist, Majority
Leader, U.S. Senate (July 17, 2003), available at
http://www.oneworld.net/article/view/66291 (last visited Dec. 29, 2003).
8. See Physicians for Human Rights, A Health Action AIDS Briefing Paper:
Administration Claims that $3 Billion Cannot Be Effectively Used To Fight Global
HIV/AIDS Are Mistaken (July 31, 2003), at
http://www.phrusa.org/campaigns/aids/briefing080403.html (last visited Nov. 10, 2003);
see also PROGRAMME COORDINATING BOARD, UNAIDS, FINANcIl. RESOURCES FOR HIV/AIDS
IV:l1 (2004)
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A second example of United States actions thwarting global efforts to
combat the HIV/AIDS pandemic was on display just two weeks prior to
President Bush's departure for Africa, when U.S. trade negotiators
attending a World Trade Organization (WTO) informal ministerial
meeting in Sharm el-Sheikh, Egypt, continued their longstanding
opposition to a straightforward, economically viable WTO deal. This deal
would have focused on how poor countries with insufficient domestic drug
manufacturing capacity could obtain exported, low-cost generic versions of
patented medicines, including medicines for HIV and its complications.9
Bush stated during his 2003 State of the Union address that "the cost of
[anti-HIV medication] has dropped from $12,000 a year to under $300 a
year," a price reduction which "places a tremendous possibility within our
grasp.... [s]eldom has history offered a greater opportunity to do so
much for so many."1° Only generic manufacturers offer antiretroviral prices
as low as $300 per year. Despite Bush's tacit endorsement of procurement
of generics as part of his own plan, his trade negotiators were blocking a
WTO agreement that would increase access to generic medicines in poor
countries.
These examples signal the pattern of contradiction between word and
deed, between best practice and political calculation, which currently
characterizes White House policies on global AIDS and access to
affordable medicines. President Bush's Administration now readily
acknowledges the magnitude of the global AIDS crisis, although earlier
comments by President Bush during a debate with Al Gore, in which Bush
stated that Africa would not be a priority for his Administration, cast a long
shadow over his presidency." This shift in rhetoric did not happen by
accident. Public pressure including coalition protests, non-violent civil
disobedience, and other forms of grassroots activism and policy work
forced the White House to express a commitment to scaling up the United
States government's response to the crisis.12 Grassroots pressure also
PROGRAMMES IN LOW- AND MIDDLE-INCOME COUNTRIES OVER THE NEXT FIvE YEARS (Nov. 28,
2002), available at http://www.public-
info.org/Pages/PagesDossiers/FINANCEMENT%20VIH/PCB13_FinancialResources-en.d
oc (last visited Dec. 16, 2003).
9. U.S. Government, Industry, Wrestle with New Approach to TRIPS and Health, INSIDE U.S.
TRADE,June 27, 2003.
10. Bush, supra note 4.
11. Derrick Z.Jackson, No Bush Gaffes, but Plenty of Holes, BOSTON GLOBE, Oct. 13, 2000,
at A23.
12. See e.g.,Jon Cohen, Tough Challenges Ahead on Political and Scientific Front, 297 SCIENCE
312 (2002); Manny Fernandez, Protesters Take AIDS Message to the White House, WASH. POST,
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helped reverse more than a decade of United States government
opposition to funding access to life-saving antiretroviral treatment.'
3
Unfortunately these changes have translated neither into full support
for the Global Fund nor an end to White House obstruction of pro-public
health trade policies that facilitate robust generic competition. The
Administration's AIDS policies are more likely to be guided by the
perceived political risk associated with supporting effective interventions
than by the evidence base supporting the need for such interventions. This
piece will focus on one such intervention, the Global Fund, and will
examine efforts by the Administration, despite its promises, to avoid
effective implementation of the Global Fund.
THE GLOBAL FUND-
AN EMERGENCY RESPONSE FORGED BY INTERNATIONAL PRESSURE
During the last four years, international AIDS activism focused
attention on the tremendous gap in access to affordable HIV treatment
that renders AIDS a death sentence for 95% of the world's 42 million HIV
positive people, and a chronic, manageable illness only for the remaining
5%. 14 AIDS activists criticized what they identified as the etiology of a
deadly "medical apartheid" that creates two standards of clinical care-one
for the rich and one for the poor. Activists highlighted:
* Pharmaceutical company pricing policies, which bear little
relation to the cost of bringing a drug to market;
* Resistance to integration of "First World" standards for clinical
care into the impoverished settings relied upon by the world's
poor;
* Trade policies, enforced by the United States, that block poor
countries from using compulsory licenses 15 and other
Nov. 27, 2002, at A8.
13. John Donnelly, Prevention Urged in AIDS Fight: Natsios Says Fund Should Spend Less on
HIV Treatment, BOSTON GLOBE,June 7, 2001, at A8; Sabin Russell, AIDS Activists in Uproar
over Official's Remarks on Africa, S.F. CHRON., June 8, 2001, at A5.
14. INTERNATIONAL HIV TREATMENT AccEss COALITION, A COMMITMENT TO AcTION FOR
EXPANDED AcCESS TO HIV/AIDS TREATMENT 3 (2002), available at
http://www.who.int/hiv/pub/arv/who-hiv 2002_24.pdf (last visited Dec. 16, 2003).
15. "Compulsory licensing" refers to government authorization for the manufacturing
of a patented product without the consent of the patent holder, breaking a patent
monopoly and resulting in competition among suppliers, and subsequendy driving down
prices. Compulsory licensing is permitted according to guidelines set out in many trade
agreements, including the WTO's Agreement on Trade-Related Aspects of Intellectual
IV:I1 (2004)
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mechanisms to promote access to cheaper generic versions of
essential medicines;
* The need for wealthy donor countries to pay their fair share, as
calculated by country wealth and global need, toward closing
the massive gap in financing AIDS treatment, prevention, and
care.
From 1999 until 2001, pressure from the emerging global social
movement 6 for treatment access forced initial changes in U.S. trade policy
regarding patents and access to affordable medicines. 7 Generic
competition was facilitated, which in some cases helped reduce the prices
offered by proprietary pharmaceutical companies for important drugs. 8
And the definition of the minimum standard for a comprehensive
response to HIV disease management in poor countries was
revolutionized."9 For the first time, the human right of universal access to
H1V treatment was being expressed not as a radical idea, but as part of a
comprehensive clinical response to the disease.
At the same time, Brazil's program of universal HIV treatment
access-made possible by government provision of low-cost, generic HIV
medicines-was dramatically reducing morbidity and mortality. Data from
Brazil clearly demonstrated that delivering triple combination therapy in a
resource poor setting worked. 20 From 1996 to 2002, Brazil experienced a
40-70% reduction in AIDS-related mortality.2 ' Treatment access was linked
with a reduction in stigma, increased hope, more rapid uptake of HIVT
testing, and potentially a reduction in infectiousness-the latter related to
Property Rights, and the North American Free Trade Agreement (NAFTA).
16. See supra note 13 and accompanying text.
17. SeeExec. Order No. 13,155, 65 Fed. Reg. 30,521 (May 12, 2000).
18. See Barton Gellman, Death Watch: The Global Response to AIDS in Africa, WASH. POST,
July 5, 2000, at Al; Barton Gellman, A Turning Point that Left Millions Behind, WASH. POST,
Dec. 28, 2000, at Al; Barton Gellman, An Unequal Calculus of Life & Death, WASH. POST, Dec.
27, 2000, at Al.
19. See Ariel Pablos-Mendez, AIDS Care Is Learnt byDoingIt, 79 BULL. WORLD HEALTH
ORG. 1153 (2001); HARvARD UNIVERSITY, CONSENSUS STATEMENT FOR ANTIRETROVIRAL
TREATMENT OF AIDS IN POOR COUNTRIES (Apr. 4, 2001), available at
http://www.cid.harvard.edu/cidinthenews/pr/consensusaids-therapy.pdf (last visited
Dec. 16, 2003).
20. Tina Rosenberg, Look at Brazil, N.Y. TIMES MAG., Jan. 28, 2001, at 26.
21. WORLD HEALTH ORG., FACT SHEET NO. 274: GLOBAL AIDS TREATMENT EMERGENCY
(Sept. 2003), available at
http://www.health.fgov.be/WHI3/krant/krantarch2003/kranttekstsept3/030924m02a-
who.htm (last visited Dec. 16, 2003).
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increased control of viral load as a result of powerful and effective
combination antiretroviral therapy.2 Finally, generic competition in Brazil
and India reduced the cost of antiretroviral treatment from $15,000 per
year to $700 per year, and then to less than a dollar per day-beating the
"best offers" of brand name companies and showing the world that anti-
HIV treatment was economically feasible.2
On April 26, 2001, United Nations Secretary General Kofi Annan
called for the creation of a Global Fund which would serve as a "war chest"
to attract the billions in new resources needed to fight AIDS and other
infectious diseases with both treatment and prevention. Annan's remarks
echoed those of activists fighting for realization of the right to access to
affordable, life-saving medicines: "[T] here has been a world-wide revolt of
public opinion. People no longer accept that the sick and dying, simply
because they are poor, should be denied drugs which have transformed
the lives of others who are better off."
24
The Global Fund is structured differently than other responses to
AIDS. Rather than an unresponsive bureaucracy, the Global Fund is
designed to be a streamlined mechanism driven by country-level demand
to attract resources and fund effective programs. Proposals incorporating
antiretroviral treatment would be explicitly eligible for Global Fund grants,
unlike many bilateral funding streams that refused to fund HIV treatment,
deeming it not "cost effective. ''25 The Global Fund was to be guided by best
practices as determined by science and human rights rather than the
dictates of foreign policy as established by one donor country or another.
For example, the Global Fund would not require that countries
procure brand name drugs. On the contrary, Global Fund policy supports
procurement of the lowest cost medicines, whether brand name or
generic.2 6  Likewise, effective prevention interventions such as
22. Thomas Quinn et al., Viral Load and Heterosexual Transmission of Human
Immunodeficiency Virus Type 1, 342 NEW ENG.J. MED. 921 (2000).
23. C. Perez-Casas et al., Untangling the Web of Price Reductions: A Pricing Guide for the
Purchase of ARVs for Developing Countries, MEDECINS SANs FRONTItREs (Apr. 24, 2003), available
at http://www.accessmed-msf.org/documents/untangling4thapril2003.pdf (last visited Dec.
16, 2003); see also Clinton Group Gets Discount For AIDS Drugs, N.Y. TIMES, Oct. 24, 2003, atA8.
24. U.N. Secretary General Kofi Annan, Address to the African Summit on HIV/AIDS,
Tuberculosis, and Other Infectious Diseases (Apr. 26, 2001), available at
http://www.cptech.org/ip/health/abuja/annan4262001.html (last visited Dec. 16, 2003).
25. INTERNATIONAL HIV TREATMENT ACCESS COALITION, supra note 14, at 12.
26. GLOBAL FUND To FIGHT AIDS, TUBERCULOSIS, AND MALARIA, GUIDELINES FOR
PROPOSALS (March 2003), available at http://www.theglobalfund.org/en/apply/proposals
(last visited Dec. 16, 2003).
IV:I1 (2004)
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comprehensive sex education, harm reduction strategies, condom access,
and needle exchange, while controversial in the United States, are
supported by the Global Fund precisely because they are proven to be
effective. In contrast, the White House favors funding for "abstinence-only"
HIV prevention efforts, which educate about abstinence as a sole
intervention, rather than incorporating it as part of a comprehensive
framework of HIV prevention options. Abstinence education alone has not
been proven effective in preventing HIV transmission, but is strongly
supported by extreme religious conservatives.27
In 2001, the United States pledged to donate a mere $200 million
dollars as a "down payment" to the Global Fund. In response to a call for
an international effort to raise the $7 to $10 billion annually needed to
turn back the tide on this disease, and to launch the first comprehensive
funding mechanism to address the related pandemics of AIDS,
tuberculosis and malaria, the United States gave a sum that totaled about a
fifth of what it spends on one cruise missile, or the budget of one
Hollywood blockbuster. 'Activists raised the possibility that, without
sufficient funding, the Global Fund would be unable to show clear clinical
results, thus shielding donors ad infinitum from committing the billions
needed for HIV treatment programs. The remaining Group of Seven
leading industrialized countries (G7) announced contributions even lower
than that of the United States, adding to the funding crisis. Activism had
created a promising and independent multilateral emergency funding
mechanism committed to supporting treatment access, but G7 donors,
lining up behind the mediocre commitment from the United States, were
refusing to fund it in proportion to their wealth.
FUNDING THE GLOBAL FUND
On May 27, 2003, before departing for the G8 Summit in Evian,
President Bush signed into law an authorizing bill, the United States
Leadership Against H1V/AIDS, Tuberculosis and Malaria Act of 2003. This
new law authorized expenditures of up to $3 billion for global AIDS
programs in 2004, including $1 billion for the Global Fund, as long as the
$1 billion from the United States did not exceed 33% of total Global Fund
contributions. 28 By July, President Bush's initial 2004 budget request asked
27. Emily Wax, Ugandans Say Talk, Not Abstinence Will Win AIDS War; Bush Likely to Hear
Dissent on Policy, WASH. POsT. July 9, 2003, at Al 8; Tina Rosenberg, On Capitol Hill, Ideology Is
Distorting an African AIDS Success, N.Y. TIMES, April 28, 2003, at A30.
28. H.R. 1298, 108th Cong. (2003) (enacted).
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for only $2 billion for global AIDS spending. Furthermore, only $200
million of this amount was earmarked for the Global Fund, despite having
approved $1 billion in the authorizing bill. This represented a one-third
decrease in the United States contribution to the Global Fund-from $350
million in 2003 to $200 million in 2004.29
During Congressional consideration of the 2004 authorizing bill, the
White House lobbied aggressively to undermine amendments that would
increase contributions to the Global Fund. Instead of allowing
appropriators to increase funding for global AIDS programs, the White
House intervened, opposing any proposal that would provide more than
$200 million for the Global Fund in 2004. Ultimately, $500 million in
appropriations for the Global Fund passed the House, with a looming veto
threat from the President.30 Following the work of House-Senate
Conferees, Congress approved $2.4 billion in global AIDS spending, $550
million allocated for the Global Fund-far less than the $1 billion
President Bush promised to the Global Fund when he signed the
authorizing bill, but incrementally more than the $200 million advocated
by the White House. l
The White House defended its reduced contribution to the Global
Fund by arguing that the nascent infrastructure of poor countries would be
unable to absorb an additional $1 billion. This argument flies in the face of
available data. "3 2 The Bush Administration's resistance to the Global Fund is
motivated not by logic and facts but by political considerations. In reality,
the cash-strapped Global Fund is the only funding mechanism currently
operational that has the capacity to absorb-and accountably award-such
sums. Religious conservatives and Congressional and White House officials
have criticized the Global Fund as being unaccountable to American
taxpayers. 3 But the United States Health and Human Services Secretary
29. U.S. STATE DEP'T, U.S. GOVERNMENT SUPPORT FOR THE FIGHT AGAINST HIV/AIDS
(June 18, 2003), available at http://www.state.gov/g/oes/rls/fs/2003/21742.htm (last
visited Dec. 29, 2003).
30. Jim Abrams, House Approves $17. 1B Foreign Aid Measure, ASSOCIATED PRESS, July 24,
2003; Sheryl G. Stolberg, House Wrangles Over Level of Spending on Global AIDS, N.Y. TIMES,
July 23, 2003, at A9.
31. The Bush Administration recently proposed a 63% reduction in funding for the
Global Fund for fiscal year 2005-from the $550 million approved for 2004 to $200 million.
U.S. Dep't of State and Int'l Assistance Programs, Budget of the United States Government,
Fiscal Year 2005 (Feb. 2, 2004).
32. See supra note 8.
33. See Press Release, Office of Congressman Joe Pitts, Rep. Pitts Decries Committee
Action on HV/AIDS Bill (April 2, 2003), available at
IV:l1 (2004)
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Tommy Thompson is the Chair of the Global Fund's Board, and the
Global Fund is subjected to regular audits by the General Accounting
Office.34 This is unlike traditional bilateral funding programs, whose
quantitative clinical accomplishments are frequently inscrutable, severely
limiting accountability.
35
THE GLOBAL FUND AND THE BUSH AIDS INITIATIVE:
COMPLEMENTS OR ADVERSARIES?
The United States has refused to promise an annual contribution to
the Global Fund that represents a fair share of the overall financial need of
the Fund. This refusal is illogical and immoral. If the Global Fund falters
and is unable to fund significant quality HIV proposals, in particular
proposals that fund HIV treatment, the success of the administration's own
PEPFAR program will also be compromised. Unlike PEPFAR, which will
not be able to show results for years, the Global Fund is the one
mechanism that is actually equipped to responsibly absorb a $1 billion
contribution, as well as the billions in donations from other donors that
the United States contribution will leverage.
G7 countries have already promised to spend between $7 and $10
billion each year fighting AIDS in low and middle-income countries, as one
of a series of targets committed to by all United Nations members. 36
UNAIDS projects that funding needs in poor countries will reach $10.5
billion by 2005, and will reach $15 billion by 2007 37-- and this is without
taking into account the funding needed to build and develop human and
non-human infrastructure. Global AIDS spending in poor countries from
all sources is estimated to be $4.7 billion-with only $1.6 billion, or 34%,
http://www.house.gov/pitts/press/releases/030402r-AIDSbillIR.htm (last visited Dec. 16,
2003).
34. U.S. GEN. ACCOUNTING OFFICE, THE GLOBAL FUND To FIGHT AIDS, TUBERCULOSIS
AND MALARIA HAS ADVANCED IN KEY AREAS, BUT DIFFICULT CHALLENGES REMAIN (May 2003),
available at http://www.gao.gov/new.items/d03601.pdf (last visited Dec. 16, 2003).
35. See Derek Link & Mark Harrington, Exploring the American Response to the AIDS
Pandemic, Treatment Action Group Report (July 2000); see also U.S. GEN. ACCOUNTING
OFFICE, U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT FIGHTS AIDS IN AFRICA, BUT BETTER
DATA NEEDED TO MEASURE IMPACT (March 2001), available at
http://www.gao.gov/new.items/d01449.pdf (last visited Dec. 3, 2003).
36. U.N. G.A., Special Session on HIV/AIDS, Declaration of Commitment (June 2001),
available at http://www.un.org/ga/aids/docs/aress262.pdf (last visited Dec. 16, 2003).
37. UNAIDS, FACT SHEET, MEETING THE NEED (Sept. 1, 2003), available at
http://www.unaids.org/Unaids/EN/media/fact+sheets.asp (last visited Nov. 10, 2003).
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from the combined multilateral and bilateral commitments of the seven
wealthiest countries in the world3 8 Current spending patterns mean
funding goals, and clinical goals whose fulfillment is dependent on money,
will be unmet as long as donor neglect continues.9
Examples of the potential synergy of the Global Fund and PEPFAR
generate additional arguments for the immediate full funding of both
programs by the United States. A multilateral mechanism like the Global
Fund is a necessary part of an effective response to the AIDS catastrophe.
Multilateral mechanisms pool donor efforts, are less affected by country
politics, have low overhead costs relative'to bilateral aid, and support the
coordination of international efforts. The lessons learned from meaningful
cooperation between civil society and government in Global Fund grant
writing and program implementation will be essential to PEPFAR's
attainment of its clinical goals, in particular the goal of treating two million
people with antiretrovirals by 2008.40
The White House appears willing, for now, not to object to the use of
PEPFAR money to purchase generic versions of medicines.4 ' What is
unclear is whether in the future, in order to respond favorably to pressure
from the pharmaceutical industry lobby, the United States will develop a
procurement policy for PEPFAR that de facto excludes most generic
suppliers, for example by subjecting suppliers to unnecessarily high
standards that do not increase patient safety but do eliminate generic
companies from eligibility. Likewise, it is unclear whether PEPFAR will
38. KAISER FAMILY FOUND., FACT SHEET, GLOBAL H1V/AIDS SUPPORT FROM G8
COUNTRIES, (May 2003), available at
http://www.kff.org/hivaids/ader.cfm?url=/commonspot/security/getle.cfm&PageID=l
4377 (last visited Dec. 16, 2003).
39. Press Release, United Nations, Two Years After Historic Session on HIV/AIDS, New
Reports Show Progress but Member Nations Fall Short of Goals (Sept. 22, 2003), available at
http://www.unic.org.in/News/2003/pr/pr66.html (last visited Dec. 16, 2003).
40. PEPFAR is already imposing artificial, external restrictions on funding for civil
society mobilization-an intervention that is a critical element of successful HIV treatment
scale-up efforts. See CTRS. FOR DISEASE CONTROL, RAPID ExPANSION OF ANTIRETROVIRAL
THERAPY PROGRAMS FOR HIV-INFECTED PERSONS IN SELECTED COUNTRIES IN AFRICA AND THE
CARIBBEAN UNDER THE PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF, available at
http://www.cdc.gov/od/pgo/funding/04080.htm (last visited Dec. 20, 2003). The Global
Fund, in contrast, permits CCM applicants to make independent determinations regarding
the proportion of spending needed to support civil society involvement in building local
demand for treatment access.
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solicit direct in-kind donations of medicine to offset additional costs and
therefore favor the procurement of brand name pharmaceuticals, despite a
resounding international consensus that in-kind donations of chronically
administered medicines decrease program sustainability
2
The Global Fund is providing grantees with funding used to procure
low-cost, generic antiretroviral medicines. This ensures that finite
resources will be used in a way that will benefit the greatest number of sick
and dying people, while increasing international acceptance of the
procurement of generic HIV medicines.3 Without adequate funding, the
ability of the Global Fund to set independent standards in the critical area
of drug procurement will likely be undermined by the competing political
interests of the private sector, to the detriment of people living with HIV.
OVERCOMING WHITE HOUSE RESISTANCE
TO EFFECTIVE RESPONSES TO THE AIDS CRISIS
An essential test of the commitment of the United States and other
wealthy donor countries to winning the war against AIDS is whether they
are committed to providing adequate levels of funding to pay for the
interventions-prevention, care, and treatment-that are the weapons in
this war. Donor nations are currently failing this test. A new paradigm in
resource mobilization, built on the mutual commitment of all partners to
contribute equitably to interventions that will most wisely use limited
resources for prevention and treatment, is desperately needed. The
current "supply-driven" system, where donor countries capriciously decide
when they will give and how much, has increased doubt that the
international community will commit the money needed to close the
massive existing funding gap, much less mobilize the additional finances
needed to expand and build new infrastructure.
During the sixth Board Meeting of the Global Fund, donor countries
on the board rejected proposals to require contributors to give based on
42. See, e.g., Alain Guilloux & Suerie Moon, Hidden Price Tags: Disease Specific Drug
Donations, Costs and Alternatives, MDECINS SANs FRONTItRES, DRUGS FOR NEGLECTED DISEASES
WORKING GROUP (2001).
43. The presence of more than one or two medicine suppliers is the factor most
strongly associated with low medicine prices. See St6phane Lucchini et al., Decrease in Prices of
Antiretroviral Drugs for Developing Countries: From Political "Philanthropy" to Regulated Markets ?,
in ECONOMICS OF AIDS AND ACCESS TO HIV/AIDS CARE IN DEVELOPING COUNTRIES, ISSUES
AND CHALLENGES 169 (J.P. Moatti et al., Agence Nationale de Recherches sur le Sida eds.,
2003), available at http://www.iaen.org/files.cgi/ 11088_part9 1n7-Luchini.pdf (last visited
Dec. 3, 2003).
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their fair share of global need. This decision imperils the "demand-driven"
ethos of the Global Fund-where recipient countries' resource gaps define
the Global Fund's outstanding funding needs. Advocates will be forced to
communicate conflicting messages-that G7 countries should contribute
proportionately to their wealth, but poor country applicants must submit
substantial requests for funding, regardless of the stinginess of donor
nations. Ultimately, this stinginess will exacerbate what the Global Fund's
Technical Review Panel has already described as the "shyness" of applicants
in requesting funding for antiretroviral treatment, a historically neglected
intervention."
The most promising models for resource mobilization have been
suggested elsewhere. 45 These support a framework in which the financial
burden of each donor country is calculated proportionately to its wealth
and to overall financial need, as determined by transparent analyses. Such
a model of "equitable contribution" would require donors to commit
prospectively to a regular, agreed upon schedule, so that continuity of care
in poor countries would be assured and sustainable, short-term and long-
term planning by government, care providers, people living with HIV, and
other experts would be possible. In this manner, donors' obligations would
be determined based on what people with HIV and people at greatest risk
of infection need, rather than what donors independently determine they
are willing to commit-the latter being the hallmark of the current,
unsuccessful global AIDS resource mobilization framework. The promises
made by donor countries to correct the global AIDS funding crisis will
continue to be broken, so long as donors resist a coherent, transparent,
and equitable framework for their contributions.
In the last four years, international demand for access to HIV
treatment for all has helped catalyze a dramatic shift in the rhetoric of
decision makers in the United States, as well as other donor countries. The
United States now claims it is willing to lead the fight against the global
AIDS epidemic. But the promises of the current Administration are worth
little without a commitment to full, sustained funding for mechanisms that
work, particularly the Global Fund as discussed above, and full support for
trade policies that prioritize public health and access to affordable generic
44. GLOBAL FUND To FIGHT AIDS, TUBERCULOSIS, AND MALARIA, SIXTH BOARD MEETING,
REPORT OF THE SECRETARIAT AND THE TECHNICAL REVIEW PANEL ON ROUND 3 PROPOSALS (Oct.
15-17, 2003).
45. See, e.g., Marie-Jos~e Mbuzenakamwe, Address at the Second International AIDS
Society Conference on HIV Pathogenesis and Treatment (July 13, 2002), available at
http://www.actupparis.org/articlel205.html (last visited Dec. 29, 2003).
IV:I1 (2004)
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medicines over the commercial interests of the proprietary pharmaceutical
industry.
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